ʻO ka lāʻau lapaʻau mai ka hui statins - kahi hoʻohālikelike kūwaho o ka molekine statin, i hui pū ʻia me kahi ʻāpana o ka mea i hoʻolele coenzyme A kū pololei ma kahi o ka hoʻopili ʻana o kēia enzyme, a me kāna ʻāpana ʻē aʻe e pani i ke kaʻina hoʻololi hômiaokilula i loko mevalonate, he mea pulu waena i ke kō o ke ana o ka molekō kolamu.

Nā hana ʻoki Ka hoʻokaʻawale a CoA ho'ēmi i nā kūlike intacellular kolamu a me ka uku hoʻonui ʻana i ka hana ʻĀpana LDL, kahi e alakaʻi ai i ka wikiwiki o ka catabolism kolamu (Xc) LDL. ^ E Ha yM. Ua loaʻa ia i kahi hopena hyp -ip-hypogipidemic dosis-hilinaʻi. ʻAʻole pili ka lāʻau lapaʻau i ka hana o ka hepatitis / lipoprotein lipasa a me ka catabolism o nā momona momona.

ʻO Akorta ka hopena maikaʻi ma ka endothelium o ka paia vascular (kahi hōʻailona o ka preclinical ma mua atherosclerosis), hoʻonui i nā waiwai o ka rheological o ke koko, he hopena antiproliferative a me antioxidant. Hōʻike ʻia ka hopena kiʻekiʻe 30 mau lā ma hope o ka hoʻomaka ʻana o ka lāʻau a noho ma hope o ka pae like.

Lapaʻau lāʻau

Hoʻomaʻamaʻa maikaʻi ka lāʻau mai ka papa hana ʻole. ʻAi ka ʻai ʻana i ka helu hāpau, bioavailability - e pili ana iā 20%. Ua hōʻea ʻo TCmax ma hope o - 3-5 mau hola, e lanakila ana i ka pā palena. Hoʻopili kiʻekiʻe i nā protein koko (90%). Hoʻopili ia i loko o ka ate, kahi e hoʻohālikelike ai i N-dimethyl,nā metabolites lactone. Hoʻokuʻu ʻia ia mai ke kino me nā feces maʻamau i nā loli ʻole.

Nā hōʻailona no ka hoʻohana ʻana

• Ke kīnā ʻana i ka meaʻai meaʻai no hypertriglyceridemia a me ka lipid-lowing therapy,
• I nā hihia ua hui pū ʻia hypercholesterolemia a i ʻole ka pae mua hypercholesterolemia, ma nā hihia hikiʻole ke hui pū, ka hui pū ʻana me kahi mea ʻai me nā hana ʻē ʻole ʻole e pili ana i ka lapaʻau ʻana (e hoʻoikaika kino, hōʻemi ka momona),
• I mea e lohi ai i ke kaʻina hoʻomohala ʻana atherosclerosis i ka wā e kauoha ai i ka lāʻau anticholesterol,
• No ka pale ʻana i nā hoʻopiʻi cardiovascular ma mua o nā mea pili i ka hoʻomohala ʻana Maʻi maʻi Ischemic.

Nā Hoʻohui

Hoʻopukaʻia nā hana kōpaʻa / ʻeha lohi, mālama kiʻekiʻe i ka akorta, myopathylactation hapaihoʻokipa piipili, ka nele o ka lactase, makahiki ma lalo o 18 makahiki.

E hoʻohana me ka mālama aka o ka poʻe maʻi me hypothyroidismi ka hopena o ka hoʻomohalaʻana myopathies, i ka elemakule, me haehae maʻihe kumu ʻole epilepsyka mea inu aluna i pili pū me nā huaʻaime nā hōʻeha nui.

Nā ʻōkuhi o Akorta no ka hoʻohana ʻana (Ke ʻano a me ka helu ʻana)

Pono ka lāʻau e hoʻowalewale i ka mua o kahi meaʻai lipid-hoʻemi haʻahaʻa a pono ke ahonui e hahai ia ia ma ka manawa o ka mālama ʻana. Koho ʻia ka nui o ka maʻi o ʻAkorta e like me ka huli ʻana o ka lipids a i ʻole nā ​​pahuhopu o ka hāpai ʻana.

Noi ʻia nā papa acorta e lawe ʻia ma kahi ʻano mua o 10 mg 1 mau lā i ka lā me ka hiki ke piʻi aʻe ma hope o 4 mau pule inā pono a 20 mg. Ke lawe nei i nā papa Acorta, ʻo nā ʻōlelo o ka hoʻohana ʻana e hōʻike i ka pono no ka nānā ʻana i ka lipid metabolism a me ka pono no ka hoʻoponopono lāʻau.

Hoʻohui

Co-hoʻokele o ka lāʻau lapaʻau me gemfibrozil hoʻonui ka ʻike rosuvastatin i loko o ke koko 2 mau manawa. Hoʻohana nui ka hoʻopaʻa ʻana i ka Acort me nā maʻi kūlohelohe waha e hoʻonui i ka AUC norgestrel a Ethinyl estradiole pono ke noʻonoʻo i ka wā e lawe ai i ka hoʻololi ʻana i nā hāmeʻe.

Hoʻohana pinepine ʻia o ka lāʻau lapaʻau me erythromycin hoʻonui i ka 20% AUC rosuvastatin. ^ E Ha yM. Lawe ʻia nā fibrates a hoʻōla nicotinic ma ka pūhaka o hypolipidemic e hoʻonui i ka hōʻeha myopathies. ^ E Ha yM. Hōʻikeʻike rosuvastatin a antacidskahi e komo ai alumini a hoʻōla hoʻolelehoʻemi i ka hoʻoweliweli ʻana rosuvastatin i ke koko ma kahi hapa o 50%. No laila, ua manaʻo ʻia e lawe i nā antacids i ka liʻiliʻi he 2 mau hola ma hope o ka lawe ʻana i nā papa.

E hoʻokuʻu i ke ʻano a me ka ʻano

Hoʻokomo ʻia ka Acorta i ke ʻano o nā papa i pani ʻia me ka poni kiʻi ʻoniʻoni: mai ka māwele i ke kukui ulaula, hoʻopuni, biconvex, ma ka wā keʻa - mai ke aniani a ke keʻokeʻo (10 mau p. In blisters, in a cardboard packle of 1-3 pack).

Helu 1 papa:

• ʻOi ka mea e ola ai: rosuvastatin - 10 a 20 mg (rosuvastatin calcium - 10.4 a i ʻole 20,8 mg),
• ʻO nā mea kōkua (10/20 mg, no kēlā): lactose monohala (ʻo ka waiū waiū) - 89.5 / 179 mg, cellulose microcrystalline - 29.82 / 59.64 mg, calcium hydrogen phosphate (E341) - 10.9 / 21.8 mg , crospovidone - 7.5 / 15 mg, magnesium stearate - 1.88 / 3.76 mg,
• Shell (10/20 mg, nīkeka): Opadry II 30K240001 ulaula (lactose monohidato (ka waiū waiū) - 2.4 / 4.8 mg, hydroxypropyl methylcellulose (hypromellose) - 1.68 / 3.36 mg, titanium dioxide - 1.413 / 2.826 mg, triacetin (glyceryl triacetate) - 0.48 / 0.96 mg, dye ʻioʻio wili ʻulaʻi - 0,027 / 0,054 mg) - 6/12 mg.

ʻLoe a me ke kākele

Lawe ʻia nā papa acorta i nā waha, me ka manaʻo ʻole o ka ʻai, holoi ʻia me ka wai. ʻO ka manawa kūpono o ka lā e lawe ai i ka lāʻau lapaʻau ʻaʻole iʻike ka hopena. ʻAʻole pono.

Ma mua o ke koho ʻana iā Akorta, pono e hoʻomaka ka mea maʻi i ka mālama ʻana i ka meaʻai lipid-hoʻohiolo maʻamau, pono e hoʻopili ʻia i ka papa o ka papa mālama holoʻokoʻa.

Koho ke kauka i ke kū hoʻokahi i ka rosuvastatin pakahi. Hoʻoholo ʻia e ke kumu o a me ke ʻano lāʻau a me nā pane ʻana, a pono pū kekahi e ʻae i nā ʻōlelo aʻoaʻo i ʻae ʻia i kēia manawa no nā piliona lipid.

Inā ʻaʻole i hōʻike ʻia e kahi kauka, ua lawe ʻia ʻo Aorta ma kahi inika mua o 10 mg 1 mau manawa i ka lā. I ka hoʻoholo ʻana i ka nui, pono nā manaʻo o kēlā me kēiaʻano cholesterol i ka mālama ʻia, a me ka mea hoʻi i hoʻomohala ʻia e nā maʻi puʻuwai a me nā hopena ʻino.

Ma hope o hoʻokahi mahina, inā pono, hiki ke hoʻonui ʻia he dosis o 2 mau manawa hiki.

Hoʻonui ʻia kahi hoʻonui hou o kēlā me kēia lā (a hiki i 40 mg) no nā mea maʻi me ka hypercholesterolemia koʻikoʻi a me ke koʻikoʻi o nā maʻi cardiovascular (ʻoi aku nā poʻe maʻi me ka hypercholesterolemia familial), ka hopena i makemake ʻia ai ka hopena i ka wā e loaʻa ai nā haʻahaʻa haʻahaʻa. Pono kēlā mau maʻi e kiaʻi ma lalo o ka mālama ʻana i nā mea lapaʻau, a pono lākou e nānā i nā hōʻailona o nā hana renal.

ʻAʻole hiki i nā mea maʻi ʻaʻole i kūkākūkā mua i ke kauka ke kuhikuhi iā Akorta ma kahi pākē o 40 mg.

Ma hope o 2 mau hebedoma mai ka hoʻomaka ʻana o ka ʻoihana, me ka piʻi ʻana o nā dosis, he pono ia e nānā i ka lipid metabolism. Wahi a kona mau hopena, hiki ke hōʻike ʻia ke koho hoʻēmi.

ʻAʻole koi ʻia ka hoʻoponopono ʻana o ka hoʻoponopono ʻia no ka poʻe maʻi maʻi.

ʻO ka hoʻonui ʻana o ka hoʻouluulu ʻana o ka rosuvastatin i hoʻomaopopo ʻia ma waena o Kina a me Iapana, pono e noʻonoʻo ʻia i ka wā i kuhikuhi ai i ka lāʻau lapaʻau.

ʻO ka palaka ākea koʻikoʻi kahi hoʻohālikelike i ka koho ʻana o Akorta i nā dosa he nui, i ke ʻano - i loko o kēlā me kēia lā o 40 mg.

No ka poʻe maʻi e lawe ana i nā genotypes c.521CC a me ka c.421AA, ʻaʻole pono ka nui o nā lā o kēlā me kēia lā ʻo Akorta ma mua o 20 mg.

I nā poʻe maʻi me ka hemahema o ka ate (ʻoi aku ma mua o 9 mau wahi ma ke kākala o ke keiki-Pugh), ʻaʻohe ʻano o ka hoʻohana ʻana i ka lāʻau. ʻO nā kūmole o ka maʻi maʻi ka maʻi ʻōpū ma ka hana ikaika.

ʻAʻole paipai ʻia ka lōʻihi o kēlā me kēia lā ʻo 40 mg inā aia kekahi mau mea e hōʻike i ka predisposition o ka mea maʻi i ka hoʻomohala ʻana i ka myopathy.

Hōʻalo ka piʻi ʻana o ka myopathy (e komo pū ana me ka rhabdomyolysis) me ka hoʻonui ʻana o ka kaila plasma o rosuvastatin, a me ma muli o ka hoʻohana pū ʻana o ka acorta me nā lāʻau lapaʻau e like me ka cyclosporine, kekahi mau proteides inhibitor HIV (me ka hoʻohui pū ʻana o ka ritonavir me ka atazanavir, tipranavir a / a i ʻole lopinavir). Inā hiki, e kuhikuhi ʻia kahi mea aʻoaʻo ʻē aʻe. Inā pono ʻoe e hoʻohana iā Acorta me kēia mau lāʻau lapaʻau i ka manawa like, pono ʻoe e hoʻoponopono i ka pōmaikaʻi i manaʻo ʻia me ka hopena hiki.

Nā papa papa maʻi 10 a me 20 mg: nā kauoha no ka hoʻohana ʻana

ʻO Acorta kahi lāʻau lapaʻau e pili ana i kahi hui lāʻau lapaʻau i kapa ʻia statins. I ka hapanui pinepine, kuhikuhi nā kauka i nā poʻe i loaʻa i ka atherosclerosis a me nā maʻi lipid metabolism ʻē aʻe i ke kino. Loaʻa kēia lāʻau lapaʻau i ke ʻano o nā papa kiʻi ʻoniʻoni liʻiliʻi. ʻO ka kala o nā papa i loko o nā aniani āpau. He puni lākou i ka lula, convex ma nā ʻaoʻao ʻelua, a ke wāwahi ʻia i loko, ke keʻokeʻo a ʻulaʻula paha.

ʻO ka mea hana nui o Akorta ʻo rosuvastatin. Eia kekahi, ʻo ka hoʻohui i ka rosuvastatin, ka hoʻohui ʻana o ka lāʻau i nā mea kōkua o ka lactose e like me ka lactose, cellulose, calcium, magnesium, crospovidone. ʻO ka uhi ʻana o nā kiʻi paʻi i nā papa ponoi ka lactose, hypromellose, titanium dioxide, triacetin a me kahi palapala hoʻomoneʻe i ka ʻano o ka hoʻohui hao. Loaʻa nā papa āpau i nā pūʻulu maʻamau o nā ʻāpana he 10.

Ka hana o ka hana

ʻO Akorta, a i ʻole, ʻo kāna mea hana nui, rosuvastatin, he mea selipiki koho maʻamau o kahi enzyme - hydroxymethylglutaryl-coenzyme A reductase, kahi i hōʻiliʻili ʻia, e kani like ka HMG-CoA. He mea nui ka HMG-CoA e pili ana i ka hoʻololi ʻana o ka hydroxy-3-methylglutaryl-coenzyme A i ka mea i kapa ʻia ʻo mevalonate, a i ʻole ka mevalonic acid.

ʻO Mevalonate kahi mua mua o ke kolamu, ʻo ka nui o ia mea ke kumu nui ka hopena no ka atherosclerosis. ʻO ke kaohi o ke kolamu a me ka wāwahi o nā lipoproteins density haʻahaʻa (LDL) e loaʻa ana i loko o ka ate. Mai aneʻi hiki iā ia ke ʻōlelo me ka pololei o ke akea ke kumu nui o ka hana o ka lāʻau.

Ke kōkua nei ka lāʻau lapaʻau e hoʻonui i ka nui o nā receptors no nā lipoproteins haʻahaʻa haʻahaʻa ma ka ʻaoʻao o nā peka o nā ate, ma muli o ke ʻano o ka hāpai ʻana i kā lākou huahana huikau i ka piʻi, a me nā lipoproteins kūʻokoʻa ʻaʻole i komo i ke kahe wai. Eia kekahi, i loko o ka ate, kahi hui kekahi o nā lipoproteins i ke kāpili ʻia - kahakaha haʻahaʻa loa (VLDL). ʻO Akorta ka mea e pale ai i kā lākou synthes a alakaʻi i ka hōʻemi o ko lākou kiʻekiʻe i ke koko o ke kanaka.

Kōkua ʻo Rosuvastatin e hoʻemi i ka nui o ka lipoprotein density low a haʻahaʻa loa, a i ka manawa like i hoʻonui ʻia i ka pae o ka "maikaʻi" kolamu - mai HDL. ʻO ka nui o ka kolamu nui, apolipoproteins B (akā, ma ka huli ʻana, e hoʻonui ai i ka ʻike o apolipoproteins A), ua hoʻemi nui ʻia ka triglycerides, ka hoʻemi iki ʻia o ka pae o ka "atherogenic" cholesterol.

Ke wehewehe aku nei kēia ʻano hana i ka hopena nui o ka lāʻau lapaʻau - lipid-hoʻohaʻahaʻa (maoli - hōʻemi i ka nui o ka momona). Hoʻokumu ʻia kēia hopena ma ka hopena o ka lāʻau lapaʻau i kuhikuhi ʻia e ke kauka. No ka hoʻokō ʻana i kahi therapeutic, ʻo ia hoʻi, he hopena kākoʻo kākoʻo, pono ia e lawe i ka lāʻau lapaʻau no hoʻokahi pule. I mea e loaʻa ai ka hopena kiʻekiʻe, "pīhoihoi", ʻehā mau pule o ka hoʻōla maʻamau a e mālama hou ʻia ka nui a me ka hoʻoponopono ʻana.

E hele pono ka noi ʻo Akorta me ke koho ʻana i nā lāʻau lapaʻau mai ka lāʻau pharmacological o nā lipid-hoʻemi haʻahaʻa i kapa ʻia ʻo fibrates, a me ke kaomi Nikotinic, e kōkua ana e hoʻonui i ke kiʻekiʻe o nā lipoproteins kiʻekiʻe.

Nā palapala ʻano:

Aia i kēlā me kēia papa pākuʻu:
mea ikaika: kalekaʻi rosuvastatin - 10,4 mg a i ka 20,8 mg (ma nā ʻōlelo o ke ʻano anhydrous, ʻo ia ka mea e like me nā kiko o ka rosuvastatin - 10.0 mg a 20,0 mg).
nā mea hoʻohālikelike:
Kikowaena papa:
no ka pā ana o 10 mg - lactose monohala (kāʻai waiū) 89.50 mg, cellulose microcrystalline 29.82 mg, calcium hydrogen phosphate (E 341) 10.90 mg, crospovidone 7.50 mg, magnesium stearate 1.88 mg,
no ka pā ana o 20 mg - lactose monohala (kāʻai waiū) 179.00 mg, cellulose microcrystalline 59.64 mg, calcium hydrogen phosphate (E 341) 21.80 mg, crospovidone 15.00 mg, magnesium stearate 3.76 mg.

Ka:
no ka nui o 10 mg - OPADRAY II 30K240001 Pink (OPADRAY II 30K240001 Pink) Lactose monohydrate (wai piha waiu) 2.40 mg, hypromellose (hydroxypropyl methylcellulose) 1.68 mg, titanium dioxide 1.413 mg, triacetin (glyceryl triacetate) 0.48 mg, iron oxide red oxide 0.027 mg 6.00 mg,
no ka nui o ka 20 mg - OPADRAY II 30K240001 Pink (OPADRAY II 30K240001 Pink) Lactose monohala (ka waiū waiū) 4.80 mg, hypromellose (hydroxypropyl methylcellulose) 3.36 mg, titanium dioxide 2.826 mg, triacetin (glyceryl triacetate) 0.96 mg hao waiahi hāpana hoʻohuihui 0.054 mg 12.00 mg.

Hoʻopili ʻia nā papa papa mai ka māpani kukui me ka ulaula, hoʻopuni, biconvex. Ma kahi hoʻomaha mai ke keʻokeʻo a hiki i ke kala kala.

Nā ʻōkuhi no ka hoʻohana ʻana i ka lāʻau lapaʻau

Ua kuhikuhi ʻia ʻo Aorta no nā ʻano like ʻole o ka lipid metabolism.

ʻO ka hōʻailona nui ka hele ʻana o ka atherosclerosis.

Hoʻohana ʻia ka lāʻau lapaʻau i ka hoʻohui ʻana i ka meaʻai e hoʻemi i ka kolamu a me nā lipoproteins density haʻahaʻa loa a me ka haʻahaʻa.

Eia kekahi, ua kau ʻia ka lāʻau lapaʻau:

• Me ka prophylactic e pili ana i nā maʻi o ka pūnaehana cardiovascular ma nā maʻi me ka ʻole o nā hōʻailona lapaʻau o ka maʻi naʻau coronary. Hoʻopili kēia ma ka myocardial infarction, stroke, hypertension. Ma kēia hihia, he mea nui ka nui o nā maʻi - no nā kāne he ʻoi aku ʻo ia ma mua o 50 mau makahiki, a no nā wahine ʻoi aku ma luna o 60. He mea kūpono hoʻi e noʻonoʻo i ka haʻahaʻa o ka kiʻekiʻe o ka lipoprotein kiʻekiʻe a me ka loaʻa o ka maʻi naʻau coronary i nā hoahānau pili kokoke
• ʻO ka hypercholesterolemia mua e like me Fredricksen a i ʻole kahi ʻano i hoʻohui ʻia he mea hoʻonui i ka cholesterol me nā kumu ʻole o waho. Ua hōʻike ʻia ka lāʻau lapaʻau ʻia he ʻano hana hou, ʻoiai inā ʻaʻole i lawa nā mea e hoʻohana ai i kaʻai a me ka hana kino e hoʻokō i nā hopena i makemake ʻia,
• ʻO ka ʻehā o ka ʻano o ka hypertriglyceridemia e like me Fredricksen ma ke ʻano he papa hana hou i ka hui pū ʻana me ka lāʻau.

ʻO nā maʻi e hoʻohana ai iā Akorty ma muli o ka hopena o ka lāʻau. No kahi pākahi o kēlā me kēia lā he 10 a 20 mg, he maʻi kūlohelohe, nā maʻi ʻehaʻeha, a me nā mea maʻi paha ma ka hana exacerbation, ua hoʻohālikelike ʻia, kahi i ka hoʻākāka a me ke ʻano biochemical i hoʻohālikelike ʻia me ka piʻi ʻana o ka nui o nā pihi ate e hoʻohālikelike ʻia i nā kumu maʻamau, kahi koʻikoʻi o ka hopena o ka renal, a me ke ʻano kūloko o ka maʻi wai. (lactose), kona hemahema a i ʻole ke kīnā lūlū ʻana, ka hiki ʻana i kahi mōʻaukala o myopathy (hōʻeha i ka naʻau), kahi kaila like ʻole o ka lāʻau lapaʻau i kapa ʻia ʻo Cyclospor i loko, he predisposition genetic i ka hoʻomohala ʻana o ka myopathy, ʻo ka manawa o ka hapai a me ka lactation i loko o nā wahine, he makahiki ʻōpio.

Ke hoʻomalu nei ʻo Akorta 40 mg i kēlā me kēia lā, pono ke hoʻohui ʻia nā contraindications e pili ana i luna:

1. Loaʻa iā ʻoe ka pilikia o ka thyroid - hypothyroidism,
2. ʻO ka hele ʻana i ka mōʻaukala pilikino a i ʻole ma hope o ke kinina o nā hihia o ka maʻi ʻōpū o ke kino,
3. ʻO ka hoʻomohala ʻana i ka myotoxicity i ka wā e lawe ai i ka lāʻau lapaʻau me kahi ʻano hana like o ka hana,
4. ʻO ke inu waiʻona momona,
5. ʻO nā kūlana e loaʻa ai ka hoʻonui ʻana ma ka pae o ka rosuvastatin i ke kino,
6. ʻO nā mea maʻi e pili ana i ka lāhui Mongoloid
7. Hoʻohui hui ʻia o nā fibrates,

Eia kekahi, ʻo kahi contraindication kahi i loaʻa i ke kino o ka mea maʻi me ka hōʻeha o ka renal hoʻokō.

Kuhi Kuhi Acorta

Loaʻa ka lāʻau lapaʻau i kahi palapala papa. Kuhi ʻia ke ʻano o nā papa, convex mai 2 ʻaoʻao. inā ua haki ka papa i ka hapalua, a laila ʻo kona kinona ka ʻulaʻula ʻulaʻula.

ʻO ka mea hoʻonā o ka lāʻau lapaʻau mai ka mālamalama mālamalama a i kahi ʻulaʻula uliuli i ke kala a ʻo ke kala o ka haki i hilinaʻi ʻia i ka dosage o ke kumu nui i ka papa papa. Loaʻa kahi lāʻau lapaʻau me ka nui o nā lāʻau rosuvastatin 10.0, 20.0 a me 40.0 milligrams.

Nā papa acorta me ka nui o 10 mg o rosuvastatin:

ʻO nā mea kōkua i loko o nā papa me kahi kaila o ka rosuvastatin 10.0 milligrams:

ʻO ka hui pūʻana o ka pūpū o ka lāʻau Akorta me kahi kaila o ka rosuvastatin 10.0 milligrams:

Hoʻopili i nā papa ʻaina me kahi waihona o 10,0 milligram rosuvastatin ma nā pōpō o 10 papa:

• ʻO ka pahu pahu me nā kuhikuhi i ka 1 blister (10 pcs),
• Ka pōpō kāleka 2 blisters (10 mau kāleka) me ka hoʻolaha ʻana
• Nā pākeke pepa me nā kauoha no ka hoʻohana ʻana me 3 blisters (10 pcs),

ʻO nā papa kolone ʻona polikula ma ka dosage he 20,0 milligrams:

ʻO nā mea kōkua i loko o nā papa me kahi kaila o ka rosuvastatin 20.0 milligrams:

ʻO ka hui pūʻana o ka pūpū o ka lāʻau Akorta me kahi kaila o ka rosuvastatin 20.0 milligrams:

Hoʻopili ʻia nā papa me ke kaila o ka rosuvastatin 20.0 milligrams i nā pōpō o 10 papa:

• ʻO ka pahu pahu me nā kauoha i ka 1 blister (10 pcs.),
• Pahu pahu 2 pahu (10 pcs.) Me ka hoʻolaha ʻana,
• ʻO ka pahu pahu me nā kauoha me 3 blisters (10 pcs.).

Akorta

Lapaʻau

ʻO ka mea hana i ka lāʻau rosuvastatin i nā waiwai e hoʻoneʻe i ka hana o ka enzyme HMG-CoA reductase, a me ka hoʻēmi ʻana i ka hana o ka waila mevalonic, ʻo ia kahi mea mua o ka hoʻōla ʻana o nā molekōkena kolesterol i nā manawa mua o kā lākou hana ʻana i nā pūnao o ke akeʻa (hepatocytes).

Me ke kōkua o ka lāʻau lapaʻau, ʻo ʻAkorta, ua hoʻemi ʻia ka nui o ka cholesterol i hoʻokahe i nā LDL, ka mea i ka wā e hoʻōla ai, hoʻomaka ka huli ʻana no nā lipoproteins molina haʻahaʻa, hopu iā lākou a kaʻi aku iā lākou i nā ʻāpana o ke akea no ka hoʻohana hou ʻana me ka hoʻohana ʻana i nā hua bile.

Mahalo i kēia hana o nā receptors, hoʻonui ʻia ka lipid catabolism, aia kahi nui o ka hoʻemi ʻana i ka nui o ka molekuhi momona molekole haʻahaʻa.

Ke kōkua nei kēia kaʻina hana i ka hoʻomaʻemaʻe i ke koko mai ka cholesterol free.

ʻO ka mea nui i ka lāʻau lapaʻau, pale aku ka rosuvastatin i nā hepatocytes a hoʻemi i kā lākou hana o nā lipids nui molika haʻahaʻa loa, e hōʻemi ana i ka synthesis o nā triglycerides.

He hopena olakino kēia lāʻau lapaʻau i ka lipoproteins, e hōʻemi ana i ko lākou synthes e nā selika ate, e hoʻohaʻahaʻa nui ana i ke kiʻekiʻe o ka lipoproteins kiʻekiʻe molekela i loko o ke koko a hoʻonui i ka hoʻoili ʻana o nā lipoproteins molekular kiʻekiʻe.

ʻO nā hana nui o ka hūnā aku i ka hoʻoneʻe ʻia ʻana o HMG-CoA mai ka lāʻau Akorta me ka nui o nā helu 10,0 milligrams o rosuvastatin:

• ʻO ka helu kumukūʻai o ka cholesterol hoʻohaʻahaʻa e 36.0%,
• ʻO ka hapa LDL i hōʻemi ʻia e 52.0%,
• Hoʻemi ka haʻahaʻa o ka triglyceride e ka 10,0%,
• Ua emi ka Apolipoproteins B ma kahi o 42.0%,
• Hoʻonuiʻia nā molekule o nā lipoproteins kiʻekiʻe-kiʻekiʻe (HDL) e 14.0%,
• ʻO Apolipoprotein I hoʻonui ʻia e 4.0%.

Nā hōʻike hoʻohalike no ka HMG-CoA reductase o ka lāʻau Akorta me kahi maʻi o ka rosuvastatin 20 mg:

• ʻO ka hoʻonui nuiʻana o ka index index hōʻemi a 40.0%,
• ʻO ka hapa haʻahaʻa lipid haʻahaʻa (LDL) i hōʻemi ʻia e 55.0%,
• ʻO ka hapa iki o nā molekika triglyceride e hoʻemi ʻia e 23.0%,
• Ua hoemi ʻia ʻo Apolipoproteins B e 46.0%,
• Aia ka hoʻonui o nā molekui lipid kiʻekiʻe-kiʻekiʻe (HDL) e 8.0%,
• ʻO ka hoʻonui aʻe o ka apolipoprotein A e ka 5.0%.

ʻO ka hopena lipid-hoʻohaʻahaʻa i ke kino ke hoʻohālikelike nei i ka hoʻomoʻa ma kahi i kuhikuhi ʻia. ʻO ka hopena therapeutic hopena e kiʻi nei i kahi manawa i loko o 7 mau lā ma hope o ka hoʻomakaʻana o Acorta.

Ma hope o 14 lā, ua loaʻa ka hopena therapeutic e 90.0%, ka mea e hōʻoia nei i ka loiloi biochemical o ke ʻano o ke ʻano o ke koko plasma me kahi kiʻi lipid.

Hoʻomaopopo ka 100.0% o ka hopena therapeutic ma hope o ka lawe ʻana i nā papa Acorta i kēlā me kēia mahina. Ma hope o ka hōʻea ʻana i ka hopena a me ka hoʻohaʻahaʻa ʻana i ka helu o nā paukū pono o ka cholesterol, hoʻomau ka lāʻau no kahi mahina ʻē aʻe.

Ua hōʻike ʻia ka hana ikaika o rosuvastatin e mālama i ka mālama ʻana i ka ʻohana a me ka ʻohana ʻohana no ka hopena hypercholesterolemia, me ka piʻi nui o ka triglycerides a i ʻole ko lākou kiʻekiʻe i ke kino.

A pūaʻe hoʻi ʻo Akorta i nā ʻano maʻi like ʻole.

ʻO nā waiwai Pharmacological

Lapaʻau lāʻau
ʻO Rosuvastatin kahi mea mālama i ka hoʻokūkū koho hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase, he enzyme e hoʻololi i ka 3-hydroxy-3-methylglutaryl-CoA i mevalonate, kahi mea mua o ka cholesterol. ʻO ka pahuhopu nui o ka hana a rosuvastatin ka ate, kahi i lawe ʻia ai ka synthesis o ka cholesterol (kolesterol) a me ka catabolism o nā lipoproteins low density (LDL). Hoʻonui ka Rosuvastatin i ka nui o nā receptors LDL ma ka ʻaoʻao o nā hepatocytes, e hoʻonui ana i ka uptake a me ka catabolism o LDL. Mālama pū kekahi i ka synthesis o lipoprotein haʻahaʻa haʻahaʻa haʻahaʻa (VLDL) i loko o nā pūpuna o ka ate, ma laila e hōʻemi ana i ka nui o ka LDL a me VLDL.
Ua hōʻemi ʻo Rosuvastatin i ka hoʻololi o ka LDL cholesterol, ka nui o ka cholesterol a me ka triglycerides (TG), e hoʻonui i ka keokeo o ka kiʻekiʻe lipoprotein cholesterol (HDL-C), a me ka hōʻemi ʻana i ka ʻaila o ka apolipoprotein B (ApoV), non-HDL cholesterol (ke kūpaʻa ʻana o ka lua minamina ka minamina i ka pae o ka kolamu) ), Cholesterol-VLDL, TG-VLDL a hoʻonui i ka ʻike o ke apolipoprotein A-I (ApoA-I). Hoʻopili ʻo Rosuvastatin i ka ratio o ka cholesterol-LDL / cholesterol-HDL, ka nui o ka cholesterol / kolesterol-HDL, cholesterol-non-HDL / cholesterol-HDL a me ApoV / ApoA-I.
ʻO ka hopena lipid-hoʻohaʻahaʻa i hoʻohālikelike i ka nui o ke ʻano o ka lāʻau i kauoha ʻia.
Hoʻomohala ka hopena therapeutic i loko o ka 1 hebedoma ma hope o ka hoʻomaka ʻana o ka hoʻomaʻamaʻa, ma hope o 2 mau pule a hiki i ka 90% o ka hopena hiki loa, ʻike pinepine ʻia ka hopena therapeutic ma hope o nā hebedoma 4 a mālama ʻia me ka mālama hou ʻana i ka lāʻau.
Pōmaikaʻi ʻo ia i nā mea maʻi me ka hypercholesterolemia me ka ʻole a me ka hypertriglyceridemia (inā paha o ka lāhui, ʻano o ka wahine a ma ʻole). i nā mea maʻi me ka maʻi mellitus a me kahi ʻano hoʻoilina o ka hypercholesterolemia familial.
Hoʻomaopopo ka hopena hoʻohui me ka fenofibrate (e pili ana i ka hoʻemi ʻana o ka manaʻo o TG) a me ka waikika nikotinic ma lipid e hoʻohaʻahaʻa i nā wai (ʻoi aku ma mua o 1 g / lā) (e pili ana i ka hoʻonui i ka hoʻolilo o ka HDL cholesterol).

Lapaʻau lāʻau
Hoʻopau: kūlohelohe kūlohelohe - 20%. Hoʻemi ka meaʻai i ka helu o ka hee ʻana. ʻO ka manawa e hiki ai i ka wikiwiki kiʻekiʻe (TCmax) he 3-5 mau hola ma hope o ka nānā ʻana. Penetrates ma o ka paepae placental.
Kahele: Hoʻokomo ʻia ka Rosuvastatin e ka pepeke, ʻo ia ke kahua o ka synt synthesis a me ka metabolism o LDL-C. Ka helu ʻōpū e pili ana i ka 134 l. Ke kamaʻilio pū me nā protein plasma koko (ma ka nui me ka albumin) - 90%.
Hāpai: 10% o nā minamina i lawe ʻia i ka palemalelo. ʻO Rosuvastatin kahi papahele non-core no ka metabolism e nā enzymes o ka pūnaehana cytochrome P450. ʻO CYP2C9 ka isoenzyme nui i komo i ka metabolism o ka rosuvastatin, ʻoiai ka mea hiki i nā CenP2C19, isoenzymes CYP2C19, CYP3A4, CYP2D6 i liʻiliʻi i ka metabolism.
ʻOi aku ma mua o 90% o kahi lāʻau lapaʻau i ka pale ʻana i ka hoʻoliʻiliʻi HMG-CoA i hāʻawi ʻia e rosuvastatin, ʻo ke koena ka metabolites. ʻO nā metabolites nui i ʻike ʻia o ka rosuvastatin ʻo nā metabolites N-dismethyl a me ka lactone. ʻO N-dismethyl ma kahi o 50% emi iki ma mua o ka rosuvastatin, nā metabolite lactone i ka maʻemaʻe i ka hoʻouluulu.
Leʻaleʻa: ua hoʻopuka nui ʻia ma ka loli ʻole (90%) ma o nā ʻalā (e komo pū ana a me nā rosuvastatin unuhi ʻia), ʻo ke koena - me nā pūlū. ʻO ka hapalua-ola (T½) ma kahi o nā hola 19. He loli ka hapalua me ke piʻi ʻana o ka nui o ka lāʻau. ʻO ka hoʻonaninani kaila geometric ka mea ma kahi o 50 l / h (coefficient of variation 21.7%). E like me nā HMG-CoA reductase inhibitors, ʻo ka hua i ka hepatic o ka rosuvastatin e pili ana i ka transporter membrane kolesterol (ka lawe ʻana i ka protein C o nā anions organik), ka mea nui i ka hana hepatic o ka wehe ʻana o ka rosuvastatin.
Ka hoʻonui ʻia o ka ʻōnaehana o ka rosuvastatin i ka pānaʻi ʻana i ka nui. ʻAʻole mālama ʻia nā loli i nā ʻōkuhi pharmacokinetic me ka hoʻohana ʻana i kēlā me kēia lā o ka lāʻau.
ʻAʻole pili ka pōpilikia a me kou makahiki i nā hopena koʻikoʻi o ka maʻi ma ka pharmacokinetics o rosuvastatin.
Ua hōʻike ʻia nā haʻawina ʻo Pharmacokinetic i ka nui o ka twofold i ka median AUC (ma lalo o ka kukū ʻana o ka manawa) a me Cmax (ka nui o ka plasma kiʻekiʻe) o ka rosuvastatin i nā mea maʻi o ka lāhui Asian (Japanese, Chinese, Filipinos, Vietnamese and Koreans) i hoʻohālikelike ʻia me ʻEulopa, India Hōʻike nā mea maʻi i ka hoʻonuiʻana i ke median AUC a me Cmax i 1, 3 mau manawa. ʻAʻole i hōʻike ʻia kahi hōʻike Pharmacokinetic i nā hopena koʻikoʻi o nā maʻi i ka pharmacokinetics ma waena o ʻEulopa a me nā ʻelele o ka lāhui ʻeleʻele.
I nā maʻi me ka hōʻemiʻole a hoʻololi ʻole i ka renal kaʻai ʻana, ʻaʻole nui ka hoʻololi o ka plasma o ka rosuvastatin a i ʻole N-dysmethyl. I nā mea maʻi me ka maikaʻi o kahi renal maikaʻi ʻole (ʻoi aku ka clearance creatinine (CC)) ʻO nā mea maʻi me ka hōʻeha pūpū
ʻAʻoheʻike me ka hoʻohana o ka lāʻau lapaʻau i nā mea maʻi me ka helu ʻoi aʻe ʻoi aʻe ma mua o ka 9 ma ke kiʻekiʻe Child-Pugh.
Me ka mālama pono
No ka lāʻau lapaʻau i loko o kēlā me kēia lā he 10 a me 20 mg: ka hopena o ka hoʻomohala ʻana i ka myopathy / rhabdomyolysis - pilikia ʻole, hypothyroidism, kahi moʻolelo pilikino a pilikino paha o ka maʻi ʻōiwi a me ka mōʻaukala o mua o ka hoʻowalewale o ka naʻau me nā HMG-CoA reductase inhibitors a i nā fibrates, ka nui o ka inu ʻona. nā kūlana i loaʻa ka piʻi ʻana o ka plasma i ka rosuvastatin, he mau makahiki ma mua o 65 mau makahiki, ka mōʻaukala o ka maʻi ate, sepsis, hypotension arterial, ka lawena hooliʻi me ka nui. Twa, trauma, loa metabolic, endocrine a electrolyte kāna hana, kipi epilepsy, lāhui (Mongoloid lāhui), concomitant pono o fibrates.
No nā lā kau i kēlā me 40 mg: hina maikaʻi ʻole (CC ma mua o 60 ml / min), ʻoi aku ma mua o 65, ka moʻolelo o ka maʻi ate, sepsis, hypotension, holomua ākea, trauma, hōʻino metabolic, endocrine a me nā electrolyte haunaele a i ʻole e hoʻokele ʻole ʻia.

Nā manaʻo no ka koho ʻana o ka lāʻau lapaʻau Akorta

Hoʻomaopopo ʻia ka lāʻau lapaʻau Rosuvastatin Canon no ka mālamaʻana i kēlā mau pehu e hoʻonui i ka index cholesterol i loko o ke koko koko:

• ʻO ka heterozygous non-hoʻoilina no ka hoʻohālikelike familial hypercholesterolemia (2A ʻano e like me Fredrickson),
• ʻO ka hypercholesterolemia primale ʻaʻole ia he etiology ʻohana,
• ʻO ka ʻano hyperlipidemia like ʻole (ʻano 2B e like me Fredrickson), ka hana ikaika o ka rosuvastatin i hana ma ke ʻano o ke kōʻai kolamu,
• Ke ʻano o ka dysbetalipoproteinemia (type 3 ma mua o Fredrickson),
• Etiology ʻohana o hypertriglyceridemia (Fredrickson ʻano 4),
• Me ka ʻano homozygous o ka hypercholesterolemia hoʻoilina, hoʻohana ʻia me kahi meaʻaiʻai a i ʻole nā ​​lāʻau kolamu ʻē aʻe. A i ʻole inā he ola ka kolamu,
• Ke hooki nei i ka holomua o ka sclerosis systemic, hoʻohui pū me ka mea ʻai.

ʻO ka pale mua ʻana o ia mau ʻōkuhi:

• Myocardial infarction
• Cerebral stroke cerebral infarction a ʻole cerebral hemorrhage,
• Ischemia ʻOa organi,
• Me ka hoʻomaikaʻi hou ʻana,
• Ma hope o 50 makahiki mau kāne a me 60 mau makahiki i nā wahine,
• E hōʻemi i ka pūhui protein C-reactive,
• ʻO nā mea maʻi me ka addot nikotine a me ka waiʻona,
• Me ka hoʻouluʻana o ka hypertension,
• ʻO ka pale ʻana o ka pectoris angina kaomi, a me nā arrhythmias.

Hoʻohālike ʻia no ka hoʻohana ʻana ma hope o kahi hōʻeha

Nā hopena hopena

Hoʻopili ʻia nā hopena ʻaoʻao i ke kino e ka neʻe o nā haʻawina ma mua.

• Nui a pinepine pinepine, ʻoi aku kēia ma mua o ka 1 hihia i nā maʻi 10,
• ʻO ka maʻamau pinepine kēia o ka 1 no nā maʻi 100,
• ʻAʻole pinepine ka hihia o kēia ka 1 i nā maʻi maʻi 1000,
• Loaʻa 1 hihia i ka 10,000 maʻi,
• Loaʻa a hōʻeha paha i nā hihia 1 kahiʻoi aʻe ma mua o 10,000 mau maʻi nā mea e lawe nei i ka lāʻau Acorta:

ʻO Tachycardia kekahi o nā hopena ʻaoʻao o ka lawe ʻana i ka lāʻau lapaʻau.

Hoʻolālā Kaila a me ka Hoʻolālā Acorta

ʻO nā lula no ka lawe ʻana i ka lāʻau lapaʻau no kahi kiʻekiʻe kiʻekiʻe o ka kolamu Akorta:

• Hoʻomaka ka hoʻomaka ʻana o nā lāʻau lapaʻau me ka lāʻau ʻo Akorta me ka ʻai hypocholesterol,
• ʻO ke ʻano holoʻokoʻa o ke ʻano me Acorta kekahi e hele pū me ka ʻai,
• Koho ʻia ke ʻano lā e ke kauka ponoʻī a kūlike hoʻi i nā kuhikuhi o ka lipogram,
• Pono ʻoe e inu i ka papa pālaha aʻaʻa ʻole ʻoe e ʻōlohelohe, a inu pū kekahi i nā wai nui.
• ʻO ka ʻōmua mua o Acorta he 10.0 milligrams, hoʻokahi manawa i ka lā, ʻaʻole i nakinaki ʻia i ke kaʻina o ka ʻai ʻana i ka meaʻai,
• E hoʻonui i ka dosage a i ʻole ke hoʻololi i ka lāʻau lapaʻau, hiki i ke kauka hele wale nō ke hana i ka analogue, akā ʻaʻole i hala ma mua o hoʻokahi mahina o ka mālama ʻana,
• ʻO ka nui loa o ka nui o kēlā me kēia lā he 40.0 milligrams, i kuhikuhi wale ʻia i ka hale haukapila ma lalo o ka mālama mau ʻana o ke ʻano lapaʻau e nā kauka.
• Kuhi ʻia ka nui loa ʻana i kēlā mau maʻi i loaʻa i kahi ʻano paʻakikī o ka atherosclerosis systemic,
• Me ka hoʻomanawanui me kahi maʻi o ka 20,0 milligrams, nānā i ka index cholesterol 2 manawa i ka malama i hoʻokahi mahina,
• Eia kekahi, i ka nui o ka dosage i kēlā me kēia lā, e kiaʻi mau i ka indexine phosphokinase index,
• ʻAʻole pono nā maʻi ʻōpio i ka hoʻoponopono ʻia ʻana.

ʻOi aku ka kiʻekiʻe o ka papa o ka mea hana ikaika i ka papa, ʻoi aku ka nui o ka hopena maikaʻiʻole i ke kino mai kona alakaʻi. ʻO ka mana o ke kime o 40.0 milligrams e hoʻopiʻi i ka hopena o ka hopena, no laila e pono ʻoe e hoʻomaka i ka lāʻau maʻi me nā haʻahaʻa haʻahaʻa.

No nā mea maʻi he nui ka hapanui o ka hoʻomohala ʻana i nā pathologies cardiac, a i ʻole nā ​​māka o ke kaila koko o ke koko, hiki i ke kauka ke kuhikuhi i kahi lāʻau lapaʻau me ka nui o ka 40.0 milligrams, akā inā wale nō ka lāʻau Akorta a i nā analogues me kahi dosis ma lalo iho, ʻaʻole ia i lawe mai i ka hopena lāʻau lapaʻau i ka hoʻohaʻahaʻa ʻana i ka index kolesterol . ^ E Ha yM.

Hiki ke hoʻonui ʻia i ka hopena o ka lāʻau hiki ke hoʻopili wale ʻia ma hope o ke ʻano o ka ʻoihana laboratorium e ka lipid spectric kaedah.

Ma muli o nā hoʻokolohua diagnostic, hoʻoholo ke kauka e pili ana i ka pono e hoʻonui i ka dosis.

ʻOi aku ka kiʻekiʻe o ka papa o ka mea ikaika i ka papa, ʻoi aku ka nui o ka hopena maikaʻiʻole i ke kino mai ka lawe ʻana

ʻO ka hoʻohana ʻana o ka lāʻau Akort i ka wā hāpai

ʻAʻole kuhikuhi ʻia ka lāʻau lapaʻau ʻo ia no nā wahine i ka manawa o ka hānau ʻana i ka pēpē, a ma ka manawa hoʻi e hānai ai i ka waiū umauma.

ʻO nā wahine o ka hānau ʻana i ka manawa o ka ʻoihana me nā lāʻau lapaʻau o ka pūʻulu statin e mālama pono i ka pale ʻana i ko lākou kino mai ke kumu hoʻolālā ʻole o kahi keiki.

Inā loaʻa kahi wahine ke hāpai i ka hapai i ka manawa e lawe i ka lāʻau Akorta, a laila pono ʻoe e hoʻopilikia koke i ka papa lāʻau a hōʻike aku i ka makuahine a me ke keiki hānau ʻole.

Nā ʻōlelo kūikawā no ka hoʻonohonoho ʻana

Ke koho ʻana i kahi maʻa o 40.0 mg i nā maʻi, pono ka mālama pono ʻana i nā ʻōhua āpau o nā renal. Inā hōʻike ka maʻi maʻi i ka hoʻonui ʻana o 5 mau kau i ka mākeke o ka phosphokinase creatine, a laila ma hope o 4 a 5 mau lā, pono ʻoe e ʻōlelo hou i ka hōʻike.

Inā hōʻike hou ka pane ʻana i nā hopena like me ka ʻike mua, a laila e hoʻomaka ʻia ka ʻoihana me ka maʻi 40.0 milligrams o Acorta.

Pono hoʻi e hoʻopau i ka mālama ʻana me ka Acorta no nā pathologies hoʻi ʻana, inā ʻoi aku ka nui o ka phosphocininase ma o 5 a i ʻole nā ​​manawa hou aʻe hoʻi.

Ke hoʻihoʻi ʻia ke kūlana maʻamau a hoʻemi ʻia ka ʻeha o ka naʻau, hiki ke hoʻomau ʻia ka lāʻau lapaʻau, akā me ka dosis o Acorta ʻaʻole i kiʻekiʻe ma mua o 20.0 milligrams. Hiki ke pono ai i ke kaʻina hana immunosuppressant.

Me ka hoʻonui ʻana o ka dosage i ka manawa o ka mālama ʻana me Akorta i ka nui loa, e kiaʻi mau i ka index lipid me ka hoʻohana ʻana i ka biochemistry me ka lipid profile, a me ka cell cell transaminases ma ka serum.

Inā ʻike ka mea maʻi i ka maʻi glucose ma mua o 6.0 mmol no kēlā me kēia pālolo, a laila hiki ke mālama ʻia me Acorta i ke ʻano o ka maʻi maʻi lua.

I ka wā mālama, pono ʻoe e mālama mau i ke kō i loko o ke koko.

ʻO ka lāʻau lapaʻau o Akorta no nā statins hanauna ʻehā me ka mea kaha rosuvastatin, a he nui nā analogue o ka hana Lūkia a me nā haole.

ʻO ke kumukūʻai o ka lāʻau lapaʻau o Akort a me nā mea hoʻohui

Hoʻohālikelike

ʻO ka hoʻohana ʻana i ka lāʻau lapaʻau Lūkini e hoʻohaʻahaʻa i ka pōkole kolamu koko hiki ke kuhikuhi wale ʻia e ke kauka hele, me ka ʻona i hoʻokū ʻia e ia, a ʻaʻole pono e loli iki ka ʻano. ʻO ka papa lāʻau lapaʻau ka hele pū ʻana me ka meaola kai kauoha kauoha.

Hoʻopā ʻia ka mālama ʻana me ka mālama mau ʻana o ka mea hele a kauka a me ka ʻike mau ʻana i ka pōkole cholesterol.

Sergey, 54 mau makahiki: 3 mau makahiki i hala aku nei ua hōʻike wau i ka atherosclerosis o nā wāwae. ʻAʻole nā ​​kai i hoʻoemi i kaʻu kolamu, a ua ʻōlelo mai ke kauka i nā statins. Ua lawe au iā Krestor noʻeono mau mahina, akā ke inu nei ka inu ʻana i kēia mau pālaha.

Ua noi ʻo ia i ke kauka e hoʻohuli iā ia me nā statins ʻē aʻe, a ua hāʻawi ʻo ia iaʻu i ka lāʻau lapaʻau o Akort. Ua mahalo wau i ka hopena, a no ke kumukūʻai o ka lāʻau Lūkia e kūpono iaʻu.

ʻAʻole wau e ʻike i kekahi hopena maikaʻi loa i ke kino, aia ma ka hoʻomaka ʻana ʻaʻohe koʻikoʻi koʻikoʻi.

ʻO Galina, he 59 makahiki: ma hope o ka hoʻomaka ʻana o ka menopause, hoʻonui nui koʻu kolamu, a hoʻomaka wau e kiʻi i ka nui nui.

Ma hope o kaʻai ʻana i ka hypocholesterol, ua pau iaʻu i ka emi ʻana o kekahi paona, akā ʻaʻole i iho nui koʻu kolamu. Ua ʻōlelo mai ke kauka iaʻu he lāʻau lapaʻau acorta.

Ma hope o 2 mau maʻi o ka lapaʻau, hoʻi hou ka kolamu i ka maʻamau, akā aia wau i ka mea ʻai.

Hoʻohana i ka wā hāpai a i ka wā o ka umauma

ʻO ka lāʻau Akorta ka maʻi contraindicated no ka hoʻohana ʻana i ka wā hāpai a ma ka wā a ka umauma. Pono nā wahine o nā makahiki hānau hānau i nā ʻano kūpono a kūpono ʻole o ka contraception. No ka mea he mea nui ka huahana cholesterol a me nā huahana biosynthesis hou no ka hoʻomohala ʻana i ka maʻi fetal, ʻoi paha ka hopena o ka hōʻemi ʻana i ka HMG-CoA reductase i mua o nā pono o ka hoʻohana ʻana i ka lāʻau lapaʻau i nā wahine hāpai. I ka hihia o ka hapai i ka wā e mālama ai, pono e hoʻokuʻu koke i ka lāʻau. ʻAʻohe ʻākepili i ka hāʻawi ʻana o ka rosuvastatin me ka waiū umauma, no laila, i ka manawa o ka umauma, pono e hoʻokuʻu ʻia ka lāʻau.

ʻ a me ke kākele

Ma mua o ka hoʻomaka ʻana i ka maʻi me ka lāʻau lapaʻau, pono e hoʻomaka ka mea maʻi e hahai i kahi laiki palupalu lipine-a me ke hoʻomau nei ma muli ia i ka wā o ka mālama ʻana. Pono ke koho o ka lāʻau lapaʻau e koho hoʻokahi i ka pahuhō o nā pahuhopu a me ka pane ʻana i ka therapeutic, me ka noʻonoʻo ʻana i nā ʻōlelo i ʻāpono ʻia i loaʻa i nā manaʻo lipid kiko.
ʻO ka lāʻau Akorta ka mea maʻamau i ka manawa, me ka manawa o ka lā, e ʻike ʻole ana i ka ʻai, me ka ʻaʻa ʻole a me ka ʻaʻa ʻana i ka papaʻa, ʻūlū piha, inu ʻana me ka wai.
ʻO ka papa hana i hoʻākāka ʻia ʻia (inā ʻaʻole i manaʻo ʻia ʻo ia ka 10 mg hoʻokahi i kēlā me kēia lā no nā poʻe maʻi ʻaʻole i lawe ma mua o ka HMG-CoA reductase inhibitors, a no nā mea maʻi i hoʻoneʻe ʻia i kēia lāʻau lapaʻau ma hope o ka mālama ʻana me nā HMG-CoA reductase inhibitors.
Inā makemake, hiki ke hoʻonui ʻia i ka lāʻau ma hope o 4 hebedoma e 20 mg.
Ma muli o ka hiki ke hoʻomohala ʻana i ka hopena o ka hopena inā ka lawe ʻana i kahi maʻi o 40 mg, hoʻohālikelike ʻia me nā haʻahaʻa haʻahaʻa, ʻo ka hoʻonui ʻana i ka huakaʻi iā 40 mg hiki ke lawe wale ʻia i nā mea maʻi me ka hypercholesterolemia koʻikoʻi a me kahi koʻikoʻi nā maʻi hoʻonāukiuki (maʻa mau i nā mea maʻi me ka hypercholesterolemia familial. ), kahi i hopena ʻia ai ka hopena i makemake ʻia o ka toga ʻana i ka wā e lawe ai i ka maʻa o 20 mg, a e nānā ʻia ma lalo o ka mākaukau olakino.
ʻAno ke kiaʻi ʻana i ka poʻe maʻi e loaʻa i ka lāʻau lapaʻau ma loko o kahi mīkala o 40 mg. ʻAʻole kōkua ʻia kahi dosage 40 mg no nā maʻi ʻaʻole i kūkā ma mua i kahi kauka. Ma hope o he 2 mau hebedoma o ka lapaʻau a me / a me ke kiʻi ʻana o ka nui o ka lāʻau o ka lāʻau, pono ka nānā ʻana i nā metabolid ka lipid (inā pono, pono ʻia ka hoʻoponopono hoʻoponopono ʻia).
I ka poʻe maʻi e lawe ana i ka lāʻau lapaʻau ma kahi maʻa o 40 mg, ʻoi ʻia ia e nānā i nā māka hana o ka hana.
I ka wā e kauoha ʻia ai me gemfibrozil, ʻaʻole pono ka nui o ka lāʻau o ka rosuvastatin i ka 10 mg / lā.
ʻAʻole pono nā poʻe maʻi i ka hoʻoponopono hoʻoponopono ʻia.
I ke aʻo ʻana i nā ʻōmole pharmacokinetic i nā poʻe maʻi e pili ana i nā ʻano like ʻole o ka lāhui, ua ʻike ʻia ka hoʻonui nui o ka ʻōnaehana o ka rosuvastatin ma waena o Iapana a me Kina. Pono e noʻonoʻo ʻia kēia ʻoiaʻiʻo i ka wā e kuhikuhi ana i ka rosuvastatin i kēia mau lālā maʻi. Hoʻohana ʻia ka hoʻohana ʻana i ka lāʻau lapaʻau ma loko o kahi hapa o 40 mg i nā maʻi maʻi o ka lāhui Mongoloid.
ʻO nā mea maʻi me ka maikaʻi ʻole o ka pūpū
I nā mea maʻi me ka hōʻemi ʻole ʻana a me ka hoʻololi ʻole, ʻaʻole i koi ʻia ka hoʻoponopono ʻana. ʻO ka hoʻohana ʻana o nā āpau āpau o ka lāʻau Akorta ua contraindicated i loko o nā mea maʻi me ka maikaʻi o ka renal maikaʻi ʻole (ʻo ka clearanine clearance ma mua o 30 ml / min).
Hoʻohana ʻia ka hoʻohana ʻana i ka lāʻau lapaʻau ma loko o kahi waihona o 40 mg i loko o nā mea maʻi me ka hana o ka renal moderole (clearanine clearance ma mua o 60 ml / min).
ʻO nā maʻi me ka palaualohi maʻa
ʻAʻoheʻike me ka hoʻohana o ka lāʻau lapaʻau i nā mea maʻi me ka helu ma luna o 9 ma ke kākuhi ʻo Childe-Pugh. ʻO ka lāʻau Akorta ua contraindicated i ka poʻe maʻi me nā maʻi o ka ate ma ka hana ikaika (me ka hoʻomau i ka hana o ka hana o ka "melamin" transaminases, me ka hoʻonui hou ʻana o ka hana o ka "ate" transaminases ma ka serum o ke koko ma mua o 3 mau manawa i hoʻohālikelike ʻia me ka palena palena o mua o ka maʻamau).